Publicaciones en colaboración con investigadores/as de Centro de Investigación Médica Aplicada (22)

2024

  1. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma

    Gut

  2. Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment

    Clinical and Molecular Hepatology, Vol. 30, Núm. 2, pp. 177-190

2022

  1. DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis

    Cancers, Vol. 14, Núm. 9

  2. Hepatic progenitor cells, senescence and IL-6 as the main players in combined hepatocellular-cholangiocarcinoma development

    Journal of Hepatology

  3. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 724-734

  4. Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures

    Gut, Vol. 71, Núm. 6, pp. 1141-1151

  5. SLU7: A New Hub of Gene Expression Regulation—From Epigenetics to Protein Stability in Health and Disease

    International Journal of Molecular Sciences, Vol. 23, Núm. 21

2021

  1. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma

    Hepatology, Vol. 73, Núm. 6, pp. 2380-2396

  2. Epigenetic biomarkers for the diagnosis and treatment of liver disease

    Cancers, Vol. 13, Núm. 6, pp. 1-15

  3. Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: Dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis

    Gut, Vol. 70, Núm. 2, pp. 388-400

  4. The splicing regulator SLU7 is required to preserve DNMT1 protein stability and DNA methylation

    Nucleic Acids Research, Vol. 49, Núm. 15, pp. 8592-8609

2020

  1. C3G is upregulated in hepatocarcinoma, contributing to tumor growth and progression and to HGF/MET pathway activation

    Cancers, Vol. 12, Núm. 8, pp. 1-22

  2. Chromatin dynamics during liver regeneration

    Seminars in Cell and Developmental Biology, Vol. 97, pp. 38-46

  3. Dual pharmacological targeting of hdacs and pde5 inhibits liver disease progression in a mouse model of biliary inflammation and fibrosis

    Cancers, Vol. 12, Núm. 12, pp. 1-27

  4. Epigenetic mechanisms in gastric cancer: Potential new therapeutic opportunities

    International Journal of Molecular Sciences, Vol. 21, Núm. 15, pp. 1-21

  5. Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?

    Cells, Vol. 9, Núm. 10

  6. Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg

    JHEP Reports, Vol. 2, Núm. 6

  7. Liquid biopsy for cancer management: A revolutionary but still limited new tool for precision medicine

    Advances in Laboratory Medicine, Vol. 1, Núm. 3

  8. Pilot multi-omic analysis of human bile from benign and malignant biliary strictures: A machine-learning approach

    Cancers, Vol. 12, Núm. 6, pp. 1-30

2019

  1. New warning signs on the road: 5-hydroxymethylcytosine-based liquid biopsy for the early detection of hepatocellular carcinoma

    Gut